Genprex (GNPX) Competitors $0.39 0.00 (-0.61%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$0.39 0.00 (-0.53%) As of 02/21/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends GNPX vs. NRSN, EGRX, MTVA, SYBX, GOVX, IPA, CLRB, NERV, MYNZ, and TRIBShould you be buying Genprex stock or one of its competitors? The main competitors of Genprex include NeuroSense Therapeutics (NRSN), Eagle Pharmaceuticals (EGRX), MetaVia (MTVA), Synlogic (SYBX), GeoVax Labs (GOVX), ImmunoPrecise Antibodies (IPA), Cellectar Biosciences (CLRB), Minerva Neurosciences (NERV), Mainz Biomed (MYNZ), and Trinity Biotech (TRIB). These companies are all part of the "pharmaceutical products" industry. Genprex vs. NeuroSense Therapeutics Eagle Pharmaceuticals MetaVia Synlogic GeoVax Labs ImmunoPrecise Antibodies Cellectar Biosciences Minerva Neurosciences Mainz Biomed Trinity Biotech Genprex (NASDAQ:GNPX) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends. Does the MarketBeat Community believe in GNPX or NRSN? Genprex received 197 more outperform votes than NeuroSense Therapeutics when rated by MarketBeat users. However, 66.67% of users gave NeuroSense Therapeutics an outperform vote while only 65.25% of users gave Genprex an outperform vote. CompanyUnderperformOutperformGenprexOutperform Votes19965.25% Underperform Votes10634.75% NeuroSense TherapeuticsOutperform Votes266.67% Underperform Votes133.33% Which has more volatility & risk, GNPX or NRSN? Genprex has a beta of -0.96, indicating that its share price is 196% less volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Do insiders and institutionals believe in GNPX or NRSN? 14.1% of Genprex shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 8.5% of Genprex shares are held by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is GNPX or NRSN more profitable? NeuroSense Therapeutics' return on equity of 0.00% beat Genprex's return on equity.Company Net Margins Return on Equity Return on Assets GenprexN/A -409.48% -269.17% NeuroSense Therapeutics N/A N/A -590.79% Which has higher valuation & earnings, GNPX or NRSN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenprexN/AN/A-$30.86MN/AN/ANeuroSense TherapeuticsN/AN/A-$11.28M-$0.64-1.70 Do analysts rate GNPX or NRSN? Genprex currently has a consensus price target of $10.00, indicating a potential upside of 2,443.88%. Given Genprex's stronger consensus rating and higher probable upside, research analysts clearly believe Genprex is more favorable than NeuroSense Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00NeuroSense Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer GNPX or NRSN? In the previous week, Genprex had 3 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 4 mentions for Genprex and 1 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 1.62 beat Genprex's score of 0.17 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genprex 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeuroSense Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryGenprex beats NeuroSense Therapeutics on 7 of the 13 factors compared between the two stocks. Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNPX vs. The Competition Export to ExcelMetricGenprexPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.36M$7.06B$5.84B$9.14BDividend YieldN/A2.76%4.76%3.85%P/E RatioN/A2.9318.2614.95Price / SalesN/A281.18434.4770.76Price / CashN/A65.9238.4235.17Price / Book0.086.717.644.65Net Income-$30.86M$138.11M$3.18B$245.69M7 Day Performance-10.84%-2.54%-1.95%-2.68%1 Month Performance-47.73%-2.00%-0.23%-2.16%1 Year Performance-91.07%-5.04%16.69%12.90% Genprex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNPXGenprex4.4834 of 5 stars$0.39-0.6%$10.00+2,443.9%-91.2%$3.36MN/A0.0020Gap UpNRSNNeuroSense Therapeutics1.19 of 5 stars$1.15-0.9%N/A-12.8%$15.71MN/A-1.8010EGRXEagle PharmaceuticalsN/A$1.20+33.3%N/A-76.1%$15.59M$316.61M0.00100MTVAMetaVia1.6222 of 5 stars$1.78+3.1%$12.00+572.6%N/A$15.38MN/A0.0010Gap UpSYBXSynlogicN/A$1.29-3.7%N/A-29.7%$15.09M$2.78M-0.3180GOVXGeoVax Labs1.7314 of 5 stars$1.58-7.4%$14.20+801.6%-24.9%$14.87M$80,000.000.0010IPAImmunoPrecise Antibodies2.9808 of 5 stars$0.47-5.4%$5.00+966.1%-77.6%$14.57M$18.16M-0.6080News CoverageCLRBCellectar Biosciences1.979 of 5 stars$0.31+4.4%$17.67+5,544.3%-90.4%$14.42MN/A-0.1810Analyst ForecastNERVMinerva Neurosciences3.2159 of 5 stars$2.09-6.0%$5.00+139.6%-79.3%$14.33MN/A-4.669Analyst ForecastNews CoverageMYNZMainz Biomed2.8764 of 5 stars$7.06-4.7%$120.00+1,599.7%-85.9%$14.10M$900,000.00-0.1130News CoverageGap UpHigh Trading VolumeTRIBTrinity Biotech0.4003 of 5 stars$0.78-6.3%N/AN/A$14.03M$56.83M-0.34480 Related Companies and Tools Related Companies NRSN Competitors EGRX Competitors MTVA Competitors SYBX Competitors GOVX Competitors IPA Competitors CLRB Competitors NERV Competitors MYNZ Competitors TRIB Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GNPX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genprex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNPX Stock Alerts